Loading...
OTCM
GIKLY
Market cap5.74bUSD
Apr 10, Last price  
4.37USD
1D
-7.02%
1Q
-7.56%
Jan 2017
-56.30%
IPO
-1.80%
Name

Grifols SA

Chart & Performance

D1W1MN
P/E
42.57
P/S
0.38
EPS
0.09
Div Yield, %
—
Shrs. gr., 5y
-0.16%
Rev. gr., 5y
8.00%
Revenues
7.21b
+9.41%
524,277,000648,797,000703,291,000814,311,000913,186,000990,730,0001,795,613,0002,620,944,0002,741,732,0003,355,384,0003,934,563,0004,049,830,0004,318,073,0004,486,724,0005,098,691,0005,340,038,0004,933,118,0006,063,967,0006,591,977,0007,212,382,000
Net income
157m
+164.55%
25,556,00045,394,00087,774,000121,728,000147,972,000115,513,00050,307,000256,686,000345,551,000470,253,000532,145,000545,456,000662,700,000596,642,000625,146,000708,990,000265,327,000208,279,00059,315,000156,920,000
CFO
902m
+333.15%
119,724,00049,076,00088,644,00073,409,00088,180,000104,252,000220,228,000507,118,000592,011,000978,928,000742,778,000553,278,000841,746,000737,428,000568,933,0001,110,336,000596,975,000-10,867,000208,283,000902,168,000
Dividend
Jun 03, 20210.222 USD/sh
Earnings
May 12, 2025

Profile

Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuum–from prevention, screening, diagnosis, and prognosis to disease and treatment monitoring–to serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.
URL
https://www.grifols.com/
IPO date
May 17, 2006
Employees
23,631
Domiciled in
ES
Incorporated in
ES

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
7,212,382
9.41%
6,591,977
8.71%
6,063,967
22.92%
Cost of revenue
4,748,719
5,752,222
4,193,577
Unusual Expense (Income)
NOPBT
2,463,663
839,755
1,870,390
NOPBT Margin
34.16%
12.74%
30.84%
Operating Taxes
231,190
43,349
90,111
Tax Rate
9.38%
5.16%
4.82%
NOPAT
2,232,473
796,406
1,780,279
Net income
156,920
164.55%
59,315
-71.52%
208,279
-21.50%
Dividends
(962)
(592)
Dividend yield
Proceeds from repurchase of equity
(3,459)
BB yield
Debt
Debt current
670,224
1,013,481
681,273
Long-term debt
10,587,337
10,330,852
10,085,796
Deferred revenue
13,807
15,123
Other long-term liabilities
1,196,112
1,919,634
1,001,788
Net debt
9,724,630
10,133,508
7,626,942
Cash flow
Cash from operating activities
902,168
208,283
(10,867)
CAPEX
(232,538)
(209,538)
(375,560)
Cash from investing activities
886,667
(397,636)
(1,978,823)
Cash from financing activities
(1,358,714)
186,045
(173,493)
FCF
3,277,494
(864,520)
(69,694)
Balance
Cash
1,003,959
645,720
591,235
Long term investments
528,972
565,105
2,548,892
Excess cash
1,172,312
881,226
2,836,929
Stockholders' equity
7,830,745
7,214,505
8,619,764
Invested Capital
18,747,007
19,271,512
16,352,845
ROIC
11.74%
4.47%
12.26%
ROCE
12.37%
4.17%
9.25%
EV
Common stock shares outstanding
680,409
679,092
1,359,610
Price
Market cap
EV
EBITDA
2,901,560
1,281,673
2,278,254
EV/EBITDA
Interest
714,765
516,060
362,629
Interest/NOPBT
29.01%
61.45%
19.39%